Sionna Therapeutics, Inc. (SION)

Market Cap	1.96B +337.0%
Revenue (ttm)	n/a
Net Income	-75.27M
EPS	-1.88
Shares Out	45.00M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	508,774
Open	46.13
Previous Close	45.24
Day's Range	43.31 - 46.46
52-Week Range	9.39 - 46.46
Beta	n/a
Analysts	Strong Buy
Price Target	48.00 (+10.24%)
Earnings Date	May 11, 2026

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2025
• Employees: 59
• Stock Exchange: NASDAQ
• Ticker Symbol: SION
• Website: https://www.sionnatx.com

Analyst Summary

According to 8 analysts, the average rating for SION stock is "Strong Buy." The 12-month stock price target is $48.0, which is an increase of 10.24% from the latest price.

Price Target

$48.0

(10.24% upside)

Analyst Consensus: Strong Buy